Company Description
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.
The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.
It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California.
The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Country | United States |
Founded | 2007 |
Industry | Medical Care Facilities |
Sector | Healthcare |
Employees | 800 |
CEO | Daniel Virnich |
Contact Details
Address: 18000 Studebaker Road, Suite 800 Cerritos, California 90703 United States | |
Phone | 562 735 3226 |
Website | theoncologyinstitute.com |
Stock Details
Ticker Symbol | TOI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001799191 |
CUSIP Number | 68236X100 |
ISIN Number | US68236X1000 |
Employer ID | 84-3562323 |
SIC Code | 8011 |
Key Executives
Name | Position |
---|---|
Dr. Daniel Virnich FACHE, M.B.A., M.D. | Chief Executive Officer and Executive Director |
Richard Alan Barasch | Chairman of the Board |
Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. | Chief Medical Officer |
Rob Carter | Chief Financial Officer |
Jeremy N. Castle M.B.A. | Chief Operations Officer |
Mark Hueppelsheuser Esq. | General Counsel |
Laura Szitar | Chief People Officer |
Jordan McInerney | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 19, 2024 | 8-K | Current Report |
Dec 6, 2024 | SCHEDULE 13G/A | Filing |
Nov 13, 2024 | 10-Q | Quarterly Report |
Nov 13, 2024 | 8-K | Current Report |
Nov 12, 2024 | 8-K | Current Report |
Sep 23, 2024 | 8-K | Current Report |
Aug 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Aug 13, 2024 | 10-Q | Quarterly Report |
Aug 13, 2024 | 8-K | Current Report |
Jun 21, 2024 | 8-K | Current Report |